Gout Study – EURELIA 2

What is the EURELIA 2 Study?

The EURELIA 2 (Effect of tigulixostat on lowering Urate level, gout flare Reduction and tophi ELimination In gout patients with hyperuricemiA 2) Study is designed to investigate the efficacy and safety of an investigational drug, tigulixostat, versus allopurinol and placebo, in adults with gout and hyperuricaemia.

What is Tigulixostat?

Tigulixostat is a non-purine selective inhibitor of xanthine oxidase. It has been designed to lower uric acid concentrations in serum by inhibiting the production of uric acid.

Primary Study Coordinator: Diann
e-mail: dmoore@obfmc.com
Phone: (662) 893-8490 Extension *3231